As AbbVie’s Challenge Falters, Vertex Looks To Build On CF Dominance
Blockbuster Potential In Late-Stage Pipeline
Executive Summary
Vertex is likely to have the cystic fibrosis market to itself for years to come, but investors are banking on it repeating that success in several new first-in-class therapy areas.
You may also be interested in...
AbbVie Gets Humira Erosion Right, But Skyrizi/Rinvoq Disappoint Investors
Humira’s US revenue declines by 26% as biosimilar adalimumab makes its debut. Follow-ons Skyrizi and Rinvoq post strong growth, but fall short of Street consensus estimates.
Vertex Spots Potential Bargain Of $60m Entry Into Complement Regulation
Vertex has acquired the full assets to a promising protease-based drug platform from Catalyst, broadening its R&D base once again.
Moderna Spotlights Lung Delivery As One Of Its mRNA 'Dreams'
The company’s emphasis on artificial intelligence has played a leading role in development of lipid nanoparticles enabling delivery of mRNA to lung tissue under a partnership with Vertex.